Trial Profile
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs MEDI 6469 (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 06 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Jan 2024.
- 13 Jul 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.